PTC Therapeutics, Inc.
NASDAQPTC Therapeutics enters the back half of July with a split personality — options traders are running one of the most bullish positioning profiles of the past year, while C-suite executives just pocketed $2.2 million at the recent highs and short sellers still hold 15.4% of the free float. The options market is the most striking divergence from the cautious-short narrative. The…
Snapshot as of 12 Jul 2026
PTC Therapeutics enters the back half of July with a split personality — options traders are running one of the most bullish positioning profiles of the past year, while C-suite executives just pocketed $2.2 million at…
PTC Therapeutics heads into the week with a stock that has rallied 15% over the past month but shed 5.2% on Thursday, while the CTO cashed out more than $2 million at the highs — a combination that puts the bull…
PTC Therapeutics heads into its June 2 earnings report with fresh analyst momentum at its back — and a CEO who has just been selling. The standout this week is Jefferies, which upgraded PTCT to Buy just today, lifting…
PTC Therapeutics kicked off the week with a double-digit rally, driven by a Q1 earnings beat that cleared the bar by $0.42 EPS and pulled analysts back into the upgrade camp — a sharp reversal from the bearish drift…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PTCT — free to start on ORTEX.
Sign up for free →Open PTCT on ORTEX